NDAORALFOR SUSPENSION, TABLET
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROVAN/ZITHROMAX COMPLIANCE PAK is a fixed-dose oral combination of trovafloxacin mesylate (a fluoroquinolone) and azithromycin dihydrate (a macrolide antibiotic) approved in 1998 for oral administration as tablets or suspension. This dual-agent pack targets bacterial infections by combining broad-spectrum fluoroquinolone and macrolide coverage. The combination leverages synergistic antimicrobial mechanisms to enhance bacterial eradication.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand team is likely in defensive/transition mode with reduced headcount and focus on margin optimization rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Jobs linked to this product are minimal (0 identified), reflecting its LOE status and commodity-like market position. Roles that do exist focus on defensive sales, managed care negotiation, and transition planning rather than innovation or growth.
Field Sales RepBrand Manager
Worked on TROVAN/ZITHROMAX COMPLIANCE PAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.